SAN DIEGO--(BUSINESS WIRE)--Critical Diagnostics announced today that a paper titled, “The Effect of Left Ventricle Remodelling On Soluble ST2 in A Cohort of Hypertensive Subjects,” published in Journal of Human Hypertension, showed that the Company’s biomarker, ST2, was useful in not only differentiating hypertensive heart failure (HHF) patients from those with hypertension (HT) with or without left ventricular hypertrophy (LVH), but also distinguishes hypertensive LVH from hypertension without LVH.
Help employers find you! Check out all the jobs and post your resume.
